B-cell Lymphoma

Showing 1 - 25 of 95

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • CD19/CD22-bispecific CAR-T cells
  • Beijing, Beijing, China
    Liang Wang
Oct 7, 2023

B-cell Lymphoma Trial in Stockholm, Uppsala (CAR20(NAP)-T, Cyclophosphamide, Fludarabine)

Not yet recruiting
  • B-cell Lymphoma
  • CAR20(NAP)-T
  • +2 more
  • Stockholm, Sweden
  • +1 more
Aug 15, 2023

B-Cell Leukemia, B-Cell Lymphoma, B-cell Tumors Trial in Kunming (Anti-CD19 Autologous CAR-T Cell Infusion)

Recruiting
  • B-Cell Leukemia
  • +2 more
  • Anti-CD19 Autologous CAR-T Cell Infusion
  • Kunming, Yunnan, China
    920th Hospital of Joint Logistics Support Force of People's Libe
Jul 9, 2023

Follicular Lymphoma, B-Cell Lymphoma, Mantle Cell Lymphoma Trial in New York (Tazemetostat Pill)

Not yet recruiting
  • Follicular Lymphoma
  • +3 more
  • Tazemetostat Pill
  • New York, New York
    Weill Cornell Medicine/NewYork-Presbyterian Hospital
Jun 28, 2023

Large B-cell Lymphoma, B-cell Lymphoma Trial in Houston (Magrolimab, Rituximab, CAR T leukapheresis)

Not yet recruiting
  • Large B-cell Lymphoma
  • B-cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Jun 29, 2023

B-Cell Lymphoma, Large B-cell Lymphoma, DLBCL, Nos Genetic Subtypes Trial in New York (19(T2)28z1xx TRAC T cell)

Recruiting
  • B-Cell Lymphoma
  • +4 more
  • 19(T2)28z1xx TRAC T cell
  • New York, New York
    Memorial Sloan Kettering Cancer Center (All Protocol Activities)
Feb 24, 2023

B-cell Lymphoma Trial in Xuzhou (ASCT+CAR-T Cell Infusion)

Recruiting
  • B-cell Lymphoma
  • ASCT+CAR-T Cell Infusion
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Feb 23, 2023

Acute Lymphoblastic Leukemia, B-cell Lymphoma, Chronic Lymphocytic Leukemia Trial in Xuzhou (allogenic CD19-CAR-NK cells)

Recruiting
  • Acute Lymphoblastic Leukemia
  • +2 more
  • allogenic CD19-CAR-NK cells
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Feb 11, 2023

Mitochondrial dysfUnction:Key Player in Doxorubicin-induced

Not yet recruiting
  • Doxorubicin Induced Cardiomyopathy
  • +3 more
  • 31-MRS at 7 Tesla (T)
  • Utrecht, Netherlands
  • +1 more
Feb 7, 2023

B-cell Lymphoma Trial in Israel, Puerto Rico, Turkey (ABBV-623, ABBV-992)

Terminated
  • B-cell Lymphoma
  • Ramat Gan, Tel-Aviv, Israel
  • +4 more
Feb 2, 2023

B-cell Lymphoma, Non Hodgkin Lymphoma, DLBCL Trial in Louisville (Cyclophosphamide, Fludarabine, ACE1831)

Recruiting
  • B-cell Lymphoma
  • +5 more
  • Louisville, Kentucky
    Norton Cancer Institute
Jan 24, 2023

Normal Subjects and Disorders of Immune System and Cancer

Recruiting
  • T-cell Lymphoma
  • +3 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 24, 2023

    Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma Trial run by the NCI (Obinutuzumab, Venetoclax, Magrolimab)

    Recruiting
    • Follicular Lymphoma
    • +4 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 20, 2023

    B-Cell Lymphoma Trial in Heidelberg, Melbourne, Nedlands (TG-1801, Ublituximab)

    Active, not recruiting
    • B-Cell Lymphoma
    • Heidelberg, Victoria, Australia
    • +2 more
    Jan 20, 2023

    Multiple Myeloma, Non-Hodgkin Lymphoma, B-Cell Lymphoma Trial in Korea, Republic of, United States (Tiragolumab,

    Active, not recruiting
    • Multiple Myeloma
    • +2 more
    • Denver, Colorado
    • +12 more
    Jan 19, 2023

    Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-cell Marginal Zone, Lymphoma, Non-Hodgkin Trial in Worldwide (LOXO-338,

    Active, not recruiting
    • Leukemia, Lymphocytic, Chronic, B-Cell
    • +6 more
    • Duarte, California
    • +8 more
    Jan 11, 2023

    B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy Trial (CTX112)

    Not yet recruiting
    • B-cell Lymphoma
    • +7 more
    • CTX112
    • (no location specified)
    Dec 12, 2022

    B-cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial (IKS03)

    Not yet recruiting
    • B-cell Non-Hodgkin Lymphoma
    • +4 more
    • (no location specified)
    Dec 7, 2022

    B-Cell Lymphoma, Non-Hodgkin Lymphoma Trial in Worldwide (Glofitamab, Obinutuzumab (G), Rituximab (R))

    Active, not recruiting
    • B-Cell Lymphoma
    • Non-Hodgkin Lymphoma
    • Birmingham, Alabama
    • +23 more
    Dec 2, 2022

    B-cell Lymphoma, B-cell Leukemia Trial in Kunming (anti-CD19 UCAR-NK cells)

    Withdrawn
    • B-cell Lymphoma
    • B-cell Leukemia
    • anti-CD19 UCAR-NK cells
    • Kunming, Yunnan, China
      Kunming Hope of Health Hospital
    Nov 27, 2022

    Hodgkin Lymphoma, B-Cell Lymphoma, Relapsed B-cell NHL Trial in Houston (Mosunetuzumab, Polatuzumab vedotin, Tafasitamab)

    Not yet recruiting
    • Hodgkin Lymphoma
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    Nov 7, 2022

    B-cell Lymphoma, Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma Trial (BN301)

    Not yet recruiting
    • B-cell Lymphoma
    • +4 more
    • (no location specified)
    Nov 9, 2022

    B-cell Lymphoma Trial in Beijing (Relmacabtagene Autoleucel, Fludarabine, Cyclophosphamide)

    Not yet recruiting
    • B-cell Lymphoma
    • Relmacabtagene Autoleucel
    • +2 more
    • Beijing, Beijing, China
    • +1 more
    Oct 19, 2022

    B-cell Lymphoma Trial in Hangzhou (PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells)

    Active, not recruiting
    • B-cell Lymphoma
    • PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells
    • Hangzhou, Zhejiang, China
      The First Affiliated Hospital, Zhejiang University School of Med
    Sep 28, 2022

    B Cell ALL, B-Cell Lymphoma, B-cell Non Hodgkin Lymphoma Trial in Hackensack, New York (Anakinra)

    Recruiting
    • B Cell ALL
    • +2 more
    • Hackensack, New Jersey
    • +1 more
    Aug 22, 2022